Abstract
Introduction
The impact of common measures to assess sarcoidosis have not been compared longitudinally
to outcomes that are meaningful to patients. We prospectively examined the relationship
of baseline measurements of sarcoidosis status to outcomes of interest to patients
longitudinally over 6 months.
Methods
Sarcoidosis patients cared for at 6 US medical centers were “phenotyped” at baseline
with measurements of pulmonary function, organ involvement, health related quality
of life (HRQoL) instruments, and their anti-sarcoidosis treatment history. These patients
were followed for 6 months by monitoring outcomes of interest to patients (OIPs) including
steps walked, calories expended, sleep, HRQoL measures, workdays missed and health
care utilization. For each baseline phenotypic measurement, patients were dichotomized
into two groups above and below a specified cutoff value. The area under the OIP versus
time curve was compared between these two groups.
Results
The cutoff values for many baseline phenotypic measures distinguished the patients
into groups with significantly different 6-month OIPs. The chosen cutoff for the patient
global estimate of health status distinguished the most OIPs (13/15). The 6-min walk
distance cutoff was associated with more OIPs than spirometric measures. All of the
HRQOL measure cutoffs were associated with many OIPs, although most of them were other
HRQOL measures.
Interpretation
Cutoffs for most of the phenotypic measures used to assess sarcoidosis distinguished
groups of sarcoidosis patients with differing OIPs over the subsequent 6 months. The
patients’ global assessment of their disease was the most accurate of these measures.
Clinical trial registration number
NCT04342403.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Respiratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sarcoidosis: patient treatment priorities.ERJ Open Res. 2018; 4
- The three tiers of screening for sarcoidosis organ involvement.Respir. Med. 2016; 113: 42-49
- Disease burden and variability in sarcoidosis.Ann Am Thorac Soc. 2017; 14: S421-s428
- Sarcoidosis in America. Analysis based on health care use.Ann Am Thorac Soc. 2016; 13: 1244-1252
- Toxicity risk from glucocorticoids in sarcoidosis patients.Respir. Med. 2017; 132: 9-14
- The burden of sarcoidosis symptoms from a patient perspective.Lung. 2019; 197: 155-161
- Patient perspectives in sarcoidosis.Curr. Opin. Pulm. Med. 2019; 25: 478-483
- Barriers to care among patients with sarcoidosis: a qualitative study.Ann Am Thorac Soc. 2021;
- Health-related quality of life of persons with sarcoidosis.Chest. 2004; 125: 997-1004
- Needs, perceptions and education in sarcoidosis: a live interactive survey of patients and partners.Lung. 2018; 196: 569-575
- ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/world association of sarcoidosis and other granulomatous disorders.Sarcoidosis Vasc. Diffuse Lung Dis. 1999; 16: 149-173
- Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline.Am. J. Respir. Crit. Care Med. 2020; 201: e26-e51
- Inference and missing data.Biometrika. 1976; 63: 581-592
- Missing data methods in longitudinal studies: a review.Test. 2009; 18: 1-43
- Endpoints in sarcoidosis: more like IPF or asthma?.Respir. Med. 2018; 138s: S3-s4
- Endpoints for clinical trials of sarcoidosis.Sarcoidosis Vasc. Diffuse Lung Dis. 2012; 29: 90-98
- The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status.Thorax. 2013; 68: 57-65
- Psychological burden associated with worse clinical outcomes in sarcoidosis.BMJ Open Respir Res. 2019; 6e000467
- Does physical training reduce fatigue in sarcoidosis?.Sarcoidosis Vasc. Diffuse Lung Dis. 2015; 32: 53-62
- Benefit of wearing an activity tracker in sarcoidosis.J. Personalized Med. 2020; 10
- Predictors of fatigue in sarcoidosis: the value of exercise testing.Respir. Med. 2016; 116: 49-54
- Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation.Br. Med. J. 1961; 2: 1165-1172
- Established and experimental medical therapy of pulmonary sarcoidosis.Eur. Respir. J. 2013; 41: 1424-1438
- Predictors of mortality in pulmonary sarcoidosis.Chest. 2018; 153: 105-113
- Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.Eur. Respir. J. 2008; 31: 1189-1196
- Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis.Respir. Med. 2008; 102: 1636-1642
- The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.Respir. Med. 2015; 109: 526-531
- Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis.Am. J. Med. Sci. 2011; 341: 196-201
- The value of a patient global assessment in management of sarcoidosis.Lung. 2021;
- A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.Am. Rev. Respir. Dis. 1992; 145: 1321-1327
- Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.Rheumatology (Oxford). 2007; 46: 296-301
- Validation of the St. George's respiratory Questionnaire in bronchiectasis.Am. J. Respir. Crit. Care Med. 1997; 156: 536-541
- The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases.Sarcoidosis Vasc. Diffuse Lung Dis. 2000; 17: 158-166
- Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability.Lung. 2019; 197: 407-413
- Comprehensive care for patients with sarcoidosis.J. Clin. Med. 2020; 9
- Quality of life assessment in sarcoidosis.Clin. Chest Med. 2015; 36: 739-750
- Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS).Br. J. Health Psychol. 2004; 9: 279-291
- The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool.Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31: 19-27
- Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.Eur. Respir. J. 2014; 44: 1296-1307
- Spirometric reference values from a sample of the general U.S. population.Am. J. Respir. Crit. Care Med. 1999; 159: 179-187
- Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force.Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28: 56-64
- The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.Med. Care. 2007; 45: S3-S11
- Validation and important differences for the sarcoidosis assessment tool. A new patient-reported outcome measure.Am. J. Respir. Crit. Care Med. 2015; 191: 786-795
Article info
Publication history
Published online: March 18, 2022
Accepted:
March 9,
2022
Received in revised form:
February 14,
2022
Received:
August 13,
2021
Identification
Copyright
© 2022 Published by Elsevier Ltd.
